Flag­ship opens hub, plants roots in the UK as gov­ern­ment aims to boost life sci­ence ecosys­tem

Last year
Startups
R&D

Up­dat­ed: In­jectable form of ar­genx drug Vyv­gart fails PhI­II study in au­toim­mune platelet dis­ease

Last year
R&D

RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

Last year
Cell/Gene Tx
Manufacturing

Aldeyra's dry eye drug gets a re­jec­tion from the FDA

Last year
FDA+

Ace­lyrin says CRO Fortrea made er­rors in tri­al of lead im­munol­o­gy drug izok­ibep

Last year
R&D

Spring­Works Ther­a­peu­tics ready to launch new­ly-ap­proved desmoid tu­mor treat­ment af­ter three-month de­lay

Last year
Pharma
FDA+

Eu­ro­pean AI start­up rais­es $24M for pro­tein de­sign soft­ware ser­vice

Last year
Financing
AI

House com­mit­tee probes FTC dis­clo­sure of con­fi­den­tial in­fo in re­view­ing Am­gen-Hori­zon deal

Last year
Law

Marks: FDA open to us­ing sin­gle-arm stud­ies for ac­cel­er­at­ed ap­proval of rare dis­ease gene ther­a­pies

Last year
Cell/Gene Tx
FDA+

Mar­ius aims to shake up typ­i­cal think­ing about testos­terone in new cam­paign

Last year
Pharma
Marketing

Lo­cal Vir­ginia gov­ern­ments add to in­sulin law­suits against Eli Lil­ly, No­vo Nordisk, Sanofi, oth­ers

Last year
Pharma
Law

Sh­iono­gi brings gen­er­a­tive AI to med­ical con­fer­ences with 'War­rior' por­trait cam­paign

Last year
AI
Pharma

US gov­ern­ment turns to more do­mes­tic phar­ma man­u­fac­tur­ing to im­prove sup­ply chain re­silience 

Last year
Pharma
Manufacturing

FDA to SCO­TUS: Set­ting the mifepri­s­tone reg­u­la­tions clock back to 2016 is 'un­jus­ti­fied'

Last year
FDA+
Law

De­spite fail­ing its PhII test, Xenon sees fu­ture for ma­jor de­pres­sion drug

Last year
R&D

As­traZeneca's KRAS deal with Yusen Jian­heng; Abeona gets a PDU­FA date

Last year
News Briefing

Feng Zhang's lat­est gene edit­ing trawl reels in 188 new CRISPR sys­tems

Last year
R&D
Discovery

Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Last year
R&D

Arv­inas gets $350M boost from in­vestors to ex­tend run­way in­to 2027

Last year
Financing

So­sei Hep­tares to take back GPCR ag­o­nist af­ter GSK changes course

Last year
Deals

Tang’s Con­cen­tra faces off with Fore­site, Or­biMed in buy­out bat­tle for strug­gling biotech The­seus

Last year
Deals

Ex­clu­sive: Ae­glea re­brands to Spyre, names new CEO in IBD race against TL1A drugs at Mer­ck, Roche and Sanofi

Last year
People

No­vo Nordisk in­vests $2.4B in French fa­cil­i­ty to ad­dress boom­ing GLP-1 de­mand

Last year
Manufacturing

Af­ter pulling Blenrep from US mar­kets, GSK plots a come­back with PhI­II mul­ti­ple myelo­ma tri­al suc­cess

Last year
R&D
First page Previous page 240241242243244245246 Next page Last page
A service from the Financial Times